Medtronic reports 18.3 percent MiniMed proration for Medtronic stock

Published on 10/13/2026 at 09:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Medtronic will accept 55,032,401 tendered shares in the exchange. Medtronic stock costs EUR 82.65 on October 13, 2026 with an 18.30 percent estimate.

Key points in brief

Medtronic reported an estimated 18.30 percent preliminary proration factor for its MiniMed exchange offer on October 12, 2026.
The company intends to accept 55,032,401 tendered Medtronic shares in exchange for 252,813,348 MiniMed shares.
Medtronic stock was trading at EUR 82.65 at Lang & Schwarz on October 13, 2026 at 9:16 a.m. CEST.
BTIG Research reduced its price target from USD 100.00 to USD 99.00 while keeping a Buy rating.

Reinraumfertigung mit Technikern bei Montage medizintechnischer Präzisionsinstrumente — Medtronic plc (ISIN IE00BTN1Y115) Reinraum-Fertigung zeigt Techniker bei der Montage medizinischer Präzisionsinstrumente sorgfältig, Illustration mit AI erstellt.

Medtronic plc (ISIN IE00BTN1Y115) was trading at EUR 82.65 at Lang & Schwarz in pre-market trading on October 13, 2026 at 9:16 a.m. CEST. The company reported an estimated 18.30 percent preliminary proration factor for its MiniMed exchange offer on October 12, 2026, according to Medtronic.

MiniMed offer reaches proration stage

Medtronic said it intends to accept 55,032,401 of the tendered ordinary shares in exchange for 252,813,348 MiniMed shares. The offer was oversubscribed, so only part of the validly tendered Medtronic shares will be accepted.

The exchange agent reported 298,024,452 validly tendered Medtronic shares, including shares submitted through guaranteed delivery procedures. The preliminary factor is subject to change when that delivery period ends.

Three dated steps shaped the split-off

On September 14, 2026, Medtronic launched the exchange offer for at least 80.10 percent of MiniMed shares, according to FinanzNachrichten. On October 7, 2026, it set the final exchange ratio at 4.5939 MiniMed shares for each accepted Medtronic share, as reported by FinanzNachrichten.

On October 12, 2026, the preliminary proration estimate placed the accepted share count at 55,032,401. The sequence matters because the transaction shifts Medtronic's remaining diabetes stake to tendering shareholders while concentrating the company on its other medical technology businesses.

What does the next step mean?

Medtronic expects to announce the final proration factor on October 14, 2026, promptly after the guaranteed delivery period ends, according to Medtronic. The company also expects to complete the separation without retaining outstanding MiniMed shares.

The next dated cash event is the quarterly dividend payment scheduled for October 16, 2026. A The Stock Observer report said BTIG Research reduced its target from USD 100.00 to USD 99.00 on October 12, 2026, while retaining a Buy rating. The same report cited a consensus target of USD 102.88 from 28 analysts, including 18 Buy ratings and 10 Hold ratings.

Price stays central before the update

Medtronic's primary listing is on the NYSE under ticker MDT. The stock closed at USD 91.93 on October 12, 2026, while its market capitalization was USD 117.7 billion and its 52-week range was USD 73.31 to USD 106.33. Those US-dollar figures provide separate home-market context and are not combined with the euro quotation.

The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.